Why the study?
Does antihypertensive drug therapy improve outcomes in people with mild hypertension (diastolic BP 90-104 mm Hg)?
Does antihypertensive drug therapy improve outcomes in people with mild hypertension (diastolic BP 90-104 mm Hg)?
Answers are grounded in this paper and cite their sources.
The publication of the MRFIT trial results calls for a reassessment of the routine use of drug treatment for mild hypertension.
PUBLICATION in this journal of the results of the Multiple Risk Factor Intervention Trial (MRFIT)¹should bring about a reassessment of the current widespread and routine use of drug treatment for most people with mild hypertension, defined as a diastolic BP between 90 and 104 mm Hg. Such patients make up about 75% of the hypertensive population, a total of at least 30 million Americans. Most American practitioners are now responding to the admonishments of hypertension experts and pharmaceutical advertisements that the "HDFP (Hypertension Detection and Follow-up Program) findings justify early and aggressive management of mild hypertension." Even before the HDFP²or any other data in support of the value of such therapy for mild hypertension were available, 92% of the physicians in New York State who responded to a questionnaire indicated they routinely gave antihypertensive drug therapy to patients with diastolic BPs between 90 and 104 mm
No takes yet. Share an insight, caveat, or question.
Norman M. Kaplan (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: